2.12
price up icon1.44%   0.03
after-market After Hours: 2.06 -0.06 -2.83%
loading
Veraxa Biotech Ag stock is traded at $2.12, with a volume of 179.12K. It is up +1.44% in the last 24 hours and down -90.03% over the past month. Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
See More
Previous Close:
$2.09
Open:
$2.08
24h Volume:
179.12K
Relative Volume:
0.52
Market Cap:
$299.78M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-23.19%
1M Performance:
-90.03%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$2.04
$2.1886
1-Week Range:
Value
$2.00
$2.917
52-Week Range:
Value
$1.70
$26.01

Veraxa Biotech Ag Stock (VRXA) Company Profile

Name
Name
Veraxa Biotech Ag
Name
Phone
-
Name
Address
-
Name
Employee
0
Name
Twitter
Name
Next Earnings Date
null
Name
Latest SEC Filings
Name
VRXA's Discussions on Twitter

Compare VRXA vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
VRXA icon
VRXA
Veraxa Biotech Ag
2.12 302.61M 0 0 0 0.00
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
477.08 121.89B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
664.45 69.52B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
862.93 54.49B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
184.44 39.11B 742.00K -1.37B -1.07B -7.0731
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
279.14 38.46B 4.29B 577.22M 641.34M 4.2086

Veraxa Biotech Ag Stock (VRXA) Latest News

pulisher
Jul 14, 2026

VERAXA Biotech Leverages AI Partnership to Advance Cancer Therapy Platform - citybuzz -

Jul 14, 2026
pulisher
Jul 13, 2026

VERAXA Biotech Appoints Carl von Halem as Interim CFO Amid Permanent Candidate Search - citybuzz -

Jul 13, 2026
pulisher
Jul 13, 2026

VERAXA Biotech (VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development - NewMediaWire

Jul 13, 2026
pulisher
Jul 13, 2026

VERAXA Biotech Partners with Ardigen to Integrate AI in Cancer Drug Development - citybuzz -

Jul 13, 2026
pulisher
Jul 13, 2026

Veraxa partners with Ardigen on AI-driven cancer target selection - Investing.com UK

Jul 13, 2026
pulisher
Jul 13, 2026

AI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipeline - EIN Presswire

Jul 13, 2026
pulisher
Jul 13, 2026

Veraxa Uses AI to Advance BiTAC Pipeline - AllSci

Jul 13, 2026
pulisher
Jul 13, 2026

VERAXA Biotech AG Announces AI Collaboration with Ardigen to Support BiTAC Cancer Therapeutics Pipeline - Quiver Quantitative

Jul 13, 2026
pulisher
Jul 13, 2026

AI partnership aims to sharpen cancer target selection at VERAXA - Stock Titan

Jul 13, 2026
pulisher
Jul 10, 2026

VERAXA Biotech names Carl von Halem as interim CFO - Investing.com

Jul 10, 2026
pulisher
Jul 10, 2026

VERAXA Biotech names Carl von Halem interim CFO as it seeks permanent successor. - Pluang

Jul 10, 2026
pulisher
Jul 10, 2026

VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister - The Manila Times

Jul 10, 2026
pulisher
Jul 10, 2026

Veraxa Biotech AG Announces CFO Changes - marketscreener.com

Jul 10, 2026
pulisher
Jul 10, 2026

VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to ... - Caledonian Record

Jul 10, 2026
pulisher
Jul 09, 2026

VERAXA Biotech (NASDAQ: VRXA) Advances Lead BiTAC(R) T-Cell Engager Program with Cell Line Development Pa - Benzinga

Jul 09, 2026
pulisher
Jul 08, 2026

VERAXA Biotech Advances Lead Cancer Drug Candidate with ATUM Cell Line Development Partnership - citybuzz -

Jul 08, 2026
pulisher
Jul 08, 2026

Diluted earnings per share (diluted EPS) of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView

Jul 08, 2026
pulisher
Jul 07, 2026

Veraxa Biotech AG Company Profile & Introduction - Moomoo

Jul 07, 2026
pulisher
Jul 07, 2026

VERAXA Biotech (VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - NewMediaWire

Jul 07, 2026
pulisher
Jul 07, 2026

Non-controlling/minority interest of Veraxa Biotech AG – BOATS:VRXAW - TradingView

Jul 07, 2026
pulisher
Jul 07, 2026

VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - Benzinga

Jul 07, 2026
pulisher
Jul 07, 2026

VRXA Price History for Veraxa Biotech Ag Stock - Barchart.com

Jul 07, 2026
pulisher
Jul 06, 2026

VRXA | Veraxa Biotech AG Ordinary Institutional Ownership - Quiver Quantitative

Jul 06, 2026
pulisher
Jul 06, 2026

VRXA | Veraxa Biotech AG Ordinary Stock Data, Price & News - Quiver Quantitative

Jul 06, 2026
pulisher
Jul 06, 2026

VERAXA Biotech (VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy - NewMediaWire

Jul 06, 2026
pulisher
Jul 06, 2026

VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy in First Half of 2026 - citybuzz -

Jul 06, 2026
pulisher
Jul 06, 2026

VERAXA Biotech Advances BiTAC Pipeline, Seeks Pharma Partnerships to Fund Cancer Therapies - citybuzz -

Jul 06, 2026
pulisher
Jul 06, 2026

VERAXA Biotech targets 2028 IND filing for lead candidate - Investing.com UK

Jul 06, 2026
pulisher
Jul 06, 2026

VERAXA Biotech targets 2028 IND filing for lead candidate By Investing.com - Investing.com South Africa

Jul 06, 2026
pulisher
Jul 06, 2026

VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy - TradingView

Jul 06, 2026
pulisher
Jul 06, 2026

The Cancer Therapy Strategy VERAXA Is Betting the Company On - Yahoo Finance

Jul 06, 2026
pulisher
Jul 06, 2026

VERAXA Biotech advances cancer therapy pipeline focusing on BiTAC technology and seeks partnerships. - Pluang

Jul 06, 2026
pulisher
Jul 06, 2026

VERAXA Biotech AG Provides Pipeline and Partnering Update, Advances BiTAC Development Strategy - Quiver Quantitative

Jul 06, 2026
pulisher
Jul 06, 2026

VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines - The Manila Times

Jul 06, 2026
pulisher
Jul 06, 2026

VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and ... - Caledonian Record

Jul 06, 2026
pulisher
Jul 06, 2026

VERAXA says its BiTAC cancer pipeline is drawing partner interest - Stock Titan

Jul 06, 2026
pulisher
Jul 02, 2026

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone - Yahoo Finance

Jul 02, 2026
pulisher
Jul 02, 2026

VERAXA Biotech (VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - NewMediaWire

Jul 02, 2026
pulisher
Jul 02, 2026

VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - USA Today

Jul 02, 2026
pulisher
Jul 02, 2026

VERAXA Biotech Begins Cell Line Development for BiTAC Cancer Therapy, Aiming to Improve Tumor Selectivity - citybuzz -

Jul 02, 2026
pulisher
Jul 02, 2026

Veraxa Biotech (VRXA) Stock Price, News & Analysis - Stock Titan

Jul 02, 2026
pulisher
Jul 02, 2026

Veraxa initiates cell line development for lead cancer therapy By Investing.com - Investing.com Nigeria

Jul 02, 2026
pulisher
Jul 02, 2026

VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program - The Manila Times

Jul 02, 2026
pulisher
Jul 02, 2026

VERAXA advances lead cancer drug toward manufacturing work with ATUM - Stock Titan

Jul 02, 2026
pulisher
Jul 01, 2026

Antibody Therapeutics Deals Signal Value Creation for Early-Stage Biotechs Like VERAXA - MEXC

Jul 01, 2026
pulisher
Jul 01, 2026

Why VERAXA Biotech (VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals - NewMediaWire

Jul 01, 2026
pulisher
Jul 01, 2026

Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sect - Benzinga

Jul 01, 2026
pulisher
Jun 28, 2026

Price to earnings forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView

Jun 28, 2026
pulisher
Jun 28, 2026

Enterprise value to EBITDA forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView

Jun 28, 2026
pulisher
Jun 27, 2026

Price to book forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView

Jun 27, 2026
pulisher
Jun 27, 2026

Price to sales forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView

Jun 27, 2026

Veraxa Biotech Ag Stock (VRXA) Financials Data

There is no financial data for Veraxa Biotech Ag (VRXA). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$109.81
price down icon 0.27%
$56.31
price up icon 1.15%
$34.89
price down icon 0.06%
$68.28
price up icon 1.25%
ONC ONC
$311.26
price up icon 1.53%
$279.14
price down icon 0.75%
Cap:     |  Volume (24h):